Disclosures: Dr. Rosenson has served on advisory boards and received consulting fees and honorarium from Abbott Labs (modest), Amgen (modest), Amaryn (modest), Astra Zeneca (modest), Genentech (modest), Grain Foods Advisory Council (modest), LipoScience (modest), GlaxoSmithKline (modest), Residual Risk Reduction Initiative (modest) and Sanofi Aventis (significant), and he has stock ownership in LipoScience, Inc (significant). Dr. Brewer, Jr. serves on advisory boards, received consulting fees and honoraria from Abbott (modest), Eli Lilly & Co (modest), Merck (significant), Pfizer, Roche (significant), and Sanofi-Aventis (modest); speaker’s bureau for Astra Zeneca (modest), Abbott (modest) Merck (modest) Pfizer (modest) and Roche (modest); and ownership interest in InfraRedDx Inc. (significant), Medicines Company (significant) and NDL Therapeutics (significant). Dr. Davidson serves on the Speaker’s Bureau and received honorarium from Abbott Labs and Merck (moderate). Dr. Fayad has served on advisory boards and received honorarium from Roche (significant) and research support from Bristol Myers Squibb (significant), GlaxoSmithKline (significant), Merck (significant), Roche (significant) and VBL (significant). Dr. Fuster reports no disclosures. Dr. Goldstein serves on advisory board and receives honorarium from InfraReDx, Inc. (significant) and has stock ownership in InfraReDx Inc. (significant). Dr. Hellerstein is co-founder and chief of the scientific advisory board for KineMed Inc. (significant) and has stockownership in KineMed Inc (significant). Dr. Jiang reports no disclosures. Dr. Phillips reports no disclosures. Dr. Remaley receives research support from Alpha Care-CRADA (modest) and KineMed, Inc. (significant). Dr. Rader serves as a consultant and receives honorarium from Ainlam (moderate), Astra Zeneca (moderate), Daiichi Sankyo (moderate), Eli Lilly & Co (moderate), Glaxo Smith Kline (moderate), Johnson & Johnson (significant), Merck (significant), Novartis (moderate), Omthera (moderate), Pfizer (moderate), Regeneron (moderate), Sanofi Aventis (moderate), and has has stock ownership in Aegerion Pharmaceuticals (significant) and Vascular Strategies (significant). Dr. Rothblat has stock ownership in Vascular Strategies (significant). Dr. Tall serves on advisory boards for CSL (modest), Merck (modest), Regulus (modest) and Roche (modest), speaker’s bureau for Merck (modest), and receives honorarium form Novartis (modest). Dr. Yvan-Charvet reports no disclosures.